The study sought to assess the efficacy, tolerability, and safety of CT-P13 versus its reference and versus adalimumab in patients with Crohn disease (CD).
Anti—tumor necrosis factor (anti-TNF) agents are an important therapy for patients with Crohn disease (CD), but given the cost of anti-TNFs, use of these agents to treat some European patients with inflammatory bowel disease has been limited. A recent study from Poland—one such nation where patients have historically had limited access to biologics but where access has increased with the introduction of biosimilars—showed that the cost-saving biosimilar infliximab CT-P13 (Inflectra, Remsima) had comparable safety and efficacy to both its reference and to adalimumab in patients with CD.
The retrospective, single-center study included a cohort of 286 Polish patients with CD. The study sought to assess the efficacy, tolerability, and safety of the biosimilar versus its reference and versus adalimumab. Patients had moderate or severe CD and an insufficient response to standard therapy. Patients were assigned to receive reference infliximab (n = 82), the biosimilar (n = 109), or adalimumab (n = 95); patients treated prior to 2014 received the reference, and those treated after, due to a change in hospital funding, were given either adalimumab or the biosimilar based on their previous treatment (more than 30% of patients had received prior anti-TNF therapy) and on patient preference.
At 12 months, there were no statistically significant differences among the reference infliximab, biosimilar, and adalimumab groups, respectively, on the following criteria:
There was a similar relapse rate between patients receiving the biosimilar (54%) and adalimumab (61%), but more patients who received reference infliximab (83%) experienced relapses during 1 year of observation, and this difference reached statistical significance (P <.001).
Adverse events (AEs) were reported in 15% of the reference group, 17% of the biosimilar group, and 9% of the adalimumab group. The most commonly reported AEs were skin reactions.
According to the authors, this study has demonstrated the safety and efficacy of the biosimilar in comparison with both its reference and with adalimumab, not only with induction, but also during 1 year of therapy, and relapse rates were lower with the biosimilar than with the reference infliximab.
Reference
Kaniewska M, Rosolowski M, Rydzewska G. The efficacy, tolerability and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn’s disease [published online July 17, 2019]. Pol Arch Intern Med. doi: 10.20452/pamw.14901.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Meta-Analysis Confirms Similar Safety, Efficacy Between Adalimumab Biosimilars, Humira
April 6th 2024A systematic review and meta-analysis of 7 randomized controlled trials found no significant differences in efficacy and safety indicators between adalimumab biosimilars and the reference product (Humira) for treatment of moderate to severe psoriasis.